Etanercept (EnbrelĀ®) therapy for chronic inflammatory demyelinating polyneuropathy Academic Article Article uri icon


MeSH Major

  • Antibodies, Anti-Idiotypic
  • Gangliosides
  • Immunoglobulin M
  • Myelin-Associated Glycoprotein


  • Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and/or variants who were refractory or intolerant of standard therapies were treated with etanercept, 25 mg twice per week. Ten patients underwent treatment, and manual muscle strength, sensory thresholds and functional abilities were tested prior to and 4-6 months after initiating therapy. Three patients had significant improvement and three others had possible improvement. Based on these preliminary observations, treatment with etanercept may be considered in patients with CIDP, who cannot undergo standard therapies, although its efficacy in CIDP needs to be examined in a double-blinded, controlled clinical trial.

publication date

  • June 15, 2003



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1016/S0022-510X(03)00010-8

PubMed ID

  • 12736082

Additional Document Info

start page

  • 19

end page

  • 21


  • 210


  • 1-2